Cassava Sciences Inc vs Pinterest Inc — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Pinterest Inc trades at $21.4 (market cap $11.63B). The key difference: Pinterest Inc is far larger — about 295.2× Cassava Sciences Inc's market cap, and Pinterest Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Pinterest Inc for 85 Days on average.
| FLNA | PINS | |
|---|---|---|
Market Cap | $39.40M | $11.63B |
Volume | 759,018 | 12,792,940 |
Sector | Health | Media |
52-Week High | $4.64 | $35.24 |
52-Week Low | $0.68 | $15.42 |
Typical Hold Time | 37 Days | 85 Days |
Enterprise Value | -$43.28M | $11.55B |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 0.26% with a bearish technical signal. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent positive FDA news regarding the clinical hold lift on simufilam for epilepsy research provides a potential catalyst. Cash flow remains negative with net cash flow of -$33.07M in 2025.
The outlook is mixed with strong analyst support (66.7% buy ratings) against fundamental challenges. Investment opportunity lies in clinical trial success, while risks include sustained cash burn and execution hurdles. The stock's low EV/EBITDA of 1.03 and P/B of 0.62 suggest undervaluation if pipeline milestones are met.
Pinterest (PINS) trades at $20.525, up 1.06% today, with a bullish technical signal from moving averages but a bearish oscillator reading. The company reported strong revenue growth to $4.22 billion in 2025, with net income of $416.86 million, and has beaten EPS estimates in recent quarters. Analyst consensus is bullish with a $27.93 price target, though insider selling and negative net cash flow trends present cautionary notes.
The outlook for PINS is positive given its revenue growth trajectory and high gross margins, but valuation multiples like a P/E of 60.38 suggest premium pricing. Risks include reliance on advertising monetization and competitive pressures. Upside potential exists if international monetization accelerates and earnings continue to exceed expectations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from recipes to cook to destinations to travel to. Founded in 2010, the platform consists of a largely female audience, at roughly two thirds of its more than 365 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features.
Read more on PINS →